Vimarsana
Biggest News Aggregation in the World

Page 2 - Randomised Control Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomised Control Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomised Control Trials Today - Breaking & Trending Today

EXCLUSIVE: Veddis Foundation invests $6.3 mn in Abhijit Banerjee's J-PAL - Vimarsana News

EXCLUSIVE: Veddis Foundation invests $6.3 mn in Abhijit Banerjee's J-PAL

Titled ‘Alliance for Scaling Policy Impact through Research and Evidence’ (ASPIRE), the initiative will help governments overcome the policy challenges that hinder poverty eradication. 

Veddis Foundation and J-PAL South Asia set up ASPIRE to accelerate evidence-based policymaking - Vimarsana News

Veddis Foundation and J-PAL South Asia set up ASPIRE to accelerate evidence-based policymaking

New Delhi [India], March 2 (ANI/NewsVoir): The Abdul Latif Jameel Poverty Action Lab (J-PAL) South Asia and Veddis Foundation announced the launch of the Alliance for Scaling Policy Impact through Research and Evidence (ASPIRE) today

Veddis Foundation and J-PAL South Asia Set up ASPIRE to Accelerate Evidence-based Policymaking - Vimarsana News

Veddis Foundation and J-PAL South Asia Set up ASPIRE to Accelerate Evidence-based Policymaking

New Delhi: The Abdul Latif Jameel Poverty Action Lab (J-PAL) South Asia and Veddis Foundation announced the launch of the Alliance for Scaling Policy Impact through Research and Evidence (ASPIRE) today. ASPIRE aims to spur the adoption of anti-povert

Administrative data can inform Kenya's rollout of CBC system - Vimarsana News

Administrative data can inform Kenya's rollout of CBC system

Academicians, policymakers, and pundits do not know whether CBC will automatically create jobs and the much-needed skills sets.

Best of 2021: Don't mention Ivermectin; it'll upset the vaccine rollout - Vimarsana News

Best of 2021: Don't mention Ivermectin; it'll upset the vaccine rollout

Ivermectin is seen as a repeat of hydroxychloroquine and not to be taken seriously. Belief in it, worthy only of derision.